US009409903B2

(12) **United States Patent**
Tao et al.

(10) **Patent No.: US 9,409,903 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS**

(71) Applicant: **NantBioScience, Inc.**, Culver City, CA (US)

(72) Inventors: **Chunlin Tao**, Newport Coast, CA (US); **Qinwei Wang**, Alhambra, CA (US); **David Ho**, Monterey Park, CA (US); **Laxman Nallan**, Alhambra, CA (US); **Tulay Polat**, Los Angeles, CA (US); **Xiaowen Sun**, Shanghai (CN); **Neil Desai**, Los Angeles, CA (US)

(73) Assignee: **NantBioScience, Inc.**, Culver, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/531,585**

(22) Filed: **Nov. 3, 2014**

(65) **Prior Publication Data**

US 2015/0057285 A1 Feb. 26, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/377,031, filed as application No. PCT/US2010/037695 on Jun. 8, 2010, now Pat. No. 8,877,924.

(60) Provisional application No. 61/185,419, filed on Jun. 9, 2009.

(51) **Int. Cl.**

C07D 417/14	(2006.01)
C07D 417/12	(2006.01)
C07D 405/14	(2006.01)
C07D 403/12	(2006.01)
C07D 403/14	(2006.01)
C07D 409/14	(2006.01)
C07D 413/14	(2006.01)

(52) **U.S. Cl.**

CPC ***C07D 417/14*** (2013.01); ***C07D 403/12*** (2013.01); ***C07D 403/14*** (2013.01); ***C07D 405/14*** (2013.01); ***C07D 409/14*** (2013.01); ***C07D 413/14*** (2013.01); ***C07D 417/12*** (2013.01)

(58) **Field of Classification Search**

USPC 514/245

IPC C07D 417/14,417/12, 405/14, 403/12

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,451,596	A	9/1995	Ullrich et al.
5,854,264	A	12/1998	Anthony et al.
5,916,596	A	6/1999	Desai et al.
6,340,683	B1	1/2002	Marzabadi et al.
6,407,238	B1	6/2002	Baron et al.
6,429,213	B1	8/2002	Xue et al.
6,440,965	B1	8/2002	Kelley et al.
6,498,165	B1	12/2002	Armstrong et al.
6,506,405	B1	1/2003	Desai et al.
6,537,579	B1	3/2003	Desai et al.
6,596,746	B1	7/2003	Das et al.
6,635,655	B1	10/2003	Jayyosi et al.
6,653,332	B2	11/2003	Jaen et al.
6,858,626	B2	2/2005	Xue et al.
6,890,915	B2	5/2005	Sheppeck et al.
6,906,053	B2	6/2005	Sheppeck et al.
6,933,272	B1	8/2005	Helmerhorst et al.
6,960,685	B2	11/2005	Watkins et al.
7,005,440	B1	2/2006	Jayyosi et al.
7,041,693	B2	5/2006	Sheppeck
7,067,539	B2	6/2006	Kozlowski et al.
7,151,118	B2	12/2006	Angell et al.
7,157,487	B2	1/2007	Nakayama et al.
7,211,671	B2	5/2007	Sheppeck et al.
7,294,624	B2	11/2007	Duan et al.
7,309,800	B2	12/2007	Angell et al.
7,312,226	B2	12/2007	Hurley et al.
7,326,712	B2	2/2008	Hurley et al.
7,326,713	B2	2/2008	Hurley et al.
7,335,662	B2	2/2008	Hurley et al.
7,345,178	B2	3/2008	Nunes et al.
7,396,843	B2	7/2008	Angell et al.
RE40,558	E	10/2008	Jayyosi et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	102119157	A	7/2011
JP	2003-511378	A	3/2003
JP	2003-519143	A	6/2003
JP	2004-516292	A	6/2004
JP	2011-522870	A	8/2011
WO	WO 99/20275	A1	4/1999
WO	WO 99/32106	A1	7/1999
WO	WO 00/43369	A1	7/2000
WO	WO 01/81311	A1	11/2001
WO	WO 01/94341	A1	12/2001

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 13/377,031, filed Jul. 3, 2012.
Abram et al., *Experimental Cell Res.*, 254, 1-13 (2000).
Abu-Duhier et al., *Br. J. Haematology*, 113, 983-988 (2001).
Agnes et al., *Gene*, 145, 283-288 (1994).
Anand et al., *Cancer Cell*, 3, 51-62 (Jan. 2003).
Anderson et al., *Advances in Immunology*, 56, 151-178 (1994).
Appleby et al., *Cell*, 70, 751-763 (Sep. 4, 1992).
Bagley et al., *Org. Biomol. Chem.*, 4, 4158-4164 (2006).
Baindur et al., *J. Med. Chem.*, 48, 1717-1720 (2005).
Baliani et al., *J. Med. Chem.*, 48, 5570-5579 (2005).

(Continued)

Primary Examiner — Shirley V Gembeh
(74) *Attorney, Agent, or Firm* — Leydig, Voit & Mayer, Ltd.

(57) **ABSTRACT**

The invention provides triazine compounds and methods of their use to modulate protein kinases and to treat diseases mediated by said protein kinases.

3 Claims, No Drawings